Physician profile
Ryan Thomas Barnes
NPI 1306200290
$2,156.24
in general payments reported to CMS, 2019-2025
25 companies · $717 in 2025
The $717 reported for 2025 was more than what 89% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $479 · 2021: $368 · 2022: $350 · 2023: $26.34 · 2024: $37.90 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,044.95 | 2020-2022 | |
| Novo Nordisk INC | $167.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $92.71 | 2025 | Farxiga, Fasenra, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $82.26 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.26 | 2019-2025 | Jardiance |
| Pfizer INC. | $66.63 | 2020-2025 | |
| Wright Medical Technology, INC. | $62.51 | 2020 | |
| Abbvie INC. | $52.39 | 2025 | |
| Inspire Medical Systems, INC. | $51.44 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $50.17 | 2025 | Shingrix, Arexvy |
| Abbott Laboratories | $48.11 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.33 | 2020-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $42.47 | 2019 | |
| Medtronic, INC. | $34.93 | 2025 | Intellis Adaptivestim, Inceptiv |
| Exact Sciences Corporation | $30.66 | 2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $26.34 | 2023 | Na |
| Verona Pharma, INC. | $24.50 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $21.66 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.02 | 2025 | Gvoke Hypopen |
| Antares Pharma, INC. | $20.12 | 2024 | Xyosted |
| Astellas Pharma US INC | $19.74 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $19.40 | 2019 | |
| Dexcom, INC. | $17.78 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $16.72 | 2025 | |
| Neurocrine Biosciences, INC. | $16.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.